Business Review · MindRx Group

Section 1 · Executive Snapshot

Where we are. What's broken. What's the upside.

The audit trail (sources), the analytical rules, the KPI dashboard, and the three-and-three diagnostic — in that order. The reader sees the rigor before the numbers.

⊕ Data Foundation — What Powers This Business Review

5 platforms connected — 2 live, 3 pending — plus 4 MH·OS artifacts built for this engagement.

⊕ Connected Platforms · 2 Live · 3 Pending

● Live

Google Ads

Feb 10 → May 10, 2026 (90 days) · 5 active programs · $124,832 spend · 621 stated conversions · $201 blended stated CPA. 5-program breakdown: Search Depression/Anxiety/ADHD $349 CPA · Search Therapy $460 · Search Psychiatry $596 · Local PMax $54 · Branded $29. Powers the channel-mix view + the parallel "stated vs treated-patient" CPA comparison.

● Live

Meta Ads

Feb 10 → May 10, 2026 (90 days) · 2 active campaigns · $2,958 spend · 7,852 clicks · $0.38 CPC · 0 captured conversions — Pixel patient-form-fill event not configured. Spend is measurable; conversion attribution is not. Pixel configuration scoped for Days 1-14.

↻ Pending

GA4

Property G-TX7C26MFBE deprecated; conversion events not flowing. Form-fill rate measurement broken. Audit existing or replace; Days 1-14 deliverable. Powers default-channel-group breakout, sources-by-CVR, organic vs paid attribution.

↻ Pending

Google Search Console

Connection initiated · first sync pending (dataset registered, no rows yet). Will power organic-search query data, branded vs non-branded volume, impression / click / position trend. Baseline ~0 organic patients in 5 years suggests very weak organic foundation.

↻ Pending

IntakeQ EHR Integration

Patient data flow blocked on legal review of data-sharing agreement. Once active, unlocks: verification pass rate signal, no-show rate, retention cohort, per-channel patient attribution. Stated 50% verification pass rate is single-source until live.

⊕ MH·OS Artifacts · 4 Powering This Review

⊕ MH·OS Artifact

Brand Brain MH·OS

Positioning, 5 messaging pillars (W2-not-1099 · in-state-only · speed-to-first · integrative layer · insurance-billed commercial-only), 6 ICP personas, voice rules, payer-panel scope. Powers ICP, voice guardrails, positioning callouts.

⊕ MH·OS Artifact

Competitive Set MH·OS

8 competitors profiled — LifeStance, Talkiatry, Two Chairs, Cerebral, Done Global, Brightside, Headway, Mindful Therapy Group — by regulatory model, primary acquisition lever, geographic reach, federal-action overhang. Powers Section 5.

⊕ MH·OS Artifact

Meeting Transcripts MH·OS

Kickoff (Anthony Grippo, 2026-04-29). Powers stated lead volume, verification rate (50%), W2 top-producer revenue ($550-600K / 6mo), capacity ceiling at 13 providers, billing-team rebuild context.

⊕ MH·OS Artifact

Business Priorities MH·OS

5 levers ranked by 90-day impact: L1 verification fix · L2 AEO greenfield · L3 review compounding · L4 Google Ads optimization · L5 PCP referral channel. Powers Section 6 opportunity sizing + sequencing.

⊕ Analytical Standards — How We Source Every Number

Five rules govern how this Business Review verifies every claim. Every numeric claim is sourced and tagged.

Channel-measurement gap. Google Ads' "conversion" event = form-fill, not treated patient. Meta Pixel isn't yet configured. Stated CPA ≠ true patient CPA. Where the conversion event ≠ the business's true unit, we present both and N/A the right side until attribution is stitched.

Source confidence. H = directly verified from a connected platform or hard kickoff fact. M = derived from primary data with stated assumptions. L = single-source claim, treated as a working input until validated.

Derived metrics show the math. Effective patient CPA, true LTV:CAC, retention curve — every KPI built from a multiplier carries a derivation block with sensitivity range and a path to upgrade confidence.

N/A is shown, not hidden. Per-channel patient CPA, retention cohort by channel, organic-search KPIs — when missing, they appear as visible N/A with the unblock path. The visibility gap is part of the diagnosis.

Prior decision-makers are encoded signal. The 5-year incumbent paid-search relationship concentrated 93% of Google budget in SEARCH. That choice likely encodes lead-quality context the BR can't see from platform data alone. Where this BR contradicts an incumbent decision, it's named — not overridden without measurement.

Source Legend: H Directly verified M Derived with stated assumptions L Single-source · validating

⊕ Central Diagnostic

The MindRx engine works — ~5,000 active patients, $10,500 LTV, ~100 new patients/month, 13 PMHNP providers near capacity M. The constraint is the conversion-to-treated-patient signal — and the trajectory is deteriorating. Google Ads spent $124,832 over the last 90 days at $201 blended stated CPA H. Three cold-acquisition Search programs run $349–$596 stated; Branded ($29) and PMax ($54) pull the blended down. Monthly stated CPA climbed from $96 (Sep '25) to $204 (Apr '26) — 2.1× in 7 months H. Apply the single-source 50% verification drop-off L and Search-program effective patient CPA lands $700–$1,200. The unlock is sequenced: stitch the patient-conversion signal → 30-day measurement → channel reallocation calls become defensible. The 5-year Search concentration encodes lead-quality context — stated CPA differences across programs reflect demand-stage mix, not pure efficiency.

New Patients / mo

~100 M

→ Stated kickoff run-rate

North star: 300 / mo

Patient LTV

$10,500 H

32 visits × $330

Healthy

Avg Insurance Payout

$330 H

per 30-min visit

~$660 / hr

Google Ads Spend (90d)

$124,832 H

Feb 10 → May 10 · 5 programs

Meta adds $2,958

Search Stated CPA Range

$349–$596 H

Dep/Anx/ADHD · Therapy · Psych

PMax $54 · Branded $29

Stated CPA 7-Month Trajectory

$96 → $204 H

↑ 2.1× · Sep '25 → Apr '26

May partial: $297

⚠ Top 3 Issues — Constraining Performance Today

Stated CPA is degrading on a 12-month trajectory: $96 → $204 (Sep '25 → Apr '26), May spike to $297 H. Cold-acquisition Search programs run $349–$596 stated CPA today; only Branded ($29) and PMax ($54) are pulling the blended down. → Without conversion-signal repair, paid trajectory worsens every month

Patient-conversion signal isn't piped to Google Ads or Meta. Google Ads optimizes against form-fill at $201 blended stated H; Meta has $2,958 of 90d spend with 0 captured conversions (Pixel patient-form-fill event not configured) H. → Every channel CPA decision is on a proxy, not a treated patient

50% verification drop-off is single-source — but doubles every CPA in flight. Kickoff figure L; sensitivity widens the Search-program effective patient CPA to $700–$1,200 / patient. → Largest single sensitivity in the revenue model, unmeasured

↑ Top 3 Opportunities — Where the Upside Sits

Patient-conversion signal as the operating KPI. Replace stated CPA with patient CPA across Google Ads + Meta + GA4. → Unblocks every other lever; ~70% of KPIs upgrade L→M or M→H M

AEO + symptom-based search authority — the compounding moat. Greenfield organic baseline (~0 patients in 5 years) H + zero AEO citations on category-defining queries. Built once, ranks for years. → +15–25 patients/mo by Day 90 M · compounds 12–24 months as paid CPC keeps inflating

Verification stage fix (mechanical lift). Same-day verification + payer-panel transparency + pre-form qualifying. Target 50% → 75%. → +$245K/mo gross at constant spend M

Section 2 · Current State Diagnosis

Funnel · Channel Mix · Creative Patterns

Three audit lenses. The funnel tells us where the engine breaks. The channel mix tells us where structural risk is concentrated. The creative section tells us why category-winning telehealth psychiatry brands compound where MindRx isn't.

Funnel Performance & The Primary Growth Constraint

The funnel can't be fully diagnosed because the patient-conversion signal isn't piped through. The 5-stage funnel below combines what's verified from Google Ads + the kickoff figures with what's currently a data gap (booked, attended, retained — gated on IntakeQ data flow). The constraint is one stage upstream of the funnel itself: verification stage drop-off. Until IntakeQ flows, every leak we name is a working hypothesis with stated sensitivity, not a finding.

L90D · MindRx
Google Ads + organic

Sessions / Reach

~12,000 / mo across channels 100% L

↓ Form-fill rate unmeasurable · GA4 deprecated H

Form Submit

~200 / mo (Google + organic + referral) ~1.7% M

↓ ~50% verification · single-source L · PRIMARY CONSTRAINT

Insurance Verified

~100 / mo qualified leads ~0.83%

↓ Booking + show rate · N/A — IntakeQ blocked

Booked + Attended

N/A — IntakeQ data flow blocked N/A

↓ First-month retention · N/A — EHR cohort blocked

Active Patient

~100 net new / mo · $10,500 LTV ~0.83%

Active Patients M

~5,000

stated · kickoff

New / mo M

~100

recent run-rate · 150–180 historical

Verification Pass L

~50%

single-source · biggest sensitivity

LTV H

$10,500

32 visits × $330

⊕ Primary Growth Constraint

The constraint is the verification stage — paired with a rising stated-CPA trajectory the BR can't yet diagnose.

Three breakages compound: (1) Stated 50% verification drop-off L roughly doubles patient CPA on every channel — single-source, unmeasured; (2) Patient-creation events don't sync back to Google Ads or Meta as offline conversions H — both platforms optimize against form-fill quality, not patient quality; (3) Stated CPA climbed $96 → $204 → $297 partial-May H — 2.1× in 7 months. ~$42K/mo of paid budget allocates against a proxy at rising rates.

Strategic implication: The conversion-signal layer is the highest-leverage single move. Every other lever (verification fix · channel reallocation · AEO · PCP) sits downstream of attribution to treated patients. At the current CPA-degradation rate, paid budgets become unsustainable inside two quarters. Stitch the layer first.

Channel Mix — Imbalance & Dependency Risk

⊕ Structural Imbalance + Dependency Risk

86% of paid spend is in three cold-acquisition Search programs at $349–$596 stated CPA. Meta is measurable but invisible. AEO is greenfield. PCP + patient referrals are informal. The mix isn't just narrow — every dollar except Branded is buying net-new demand at rising rates.

Concentrated · Risk

Search · 3 Cold-Acquisition Programs

$110K of $128K 90d spend (86%) · $349–$596 stated CPA H · trajectory $96→$204 over 7 mo

5-year incumbent agency relationship. The cold-acquisition programs are doing net-new demand-gen that Branded + PMax cannot replace. Reallocation calls await the patient-CPA signal.

Misallocated · Broken Signal

Meta Ads

$2,958 90d spend H · 7,852 clicks · $0.38 CPC · 0 captured conversions (Pixel patient-form-fill event not configured)

Spend is measurable; conversion attribution is not. Days 1-14 Pixel fix unblocks measurement; until then, Meta patient CPA = N/A.

Latent · Compounding Asset

AEO + PCP + Patient Referral

~0 organic patients in 5 years H · 2 informal PCPs · 0 formal patient-referral flow on 5K active panel

All near-zero CAC, structurally defensible. With paid CPA rising 2.1× over 7 months, these are the lanes that bend the trajectory.

Measured Spend Mix · 90d H

$127.8K

Total Spend

Search · Dep/Anx/ADHD 38%

Search · Therapy 25%

Search · Psychiatry 23%

PMax · Local 7%

Branded + Meta 7%

Stated CPA by Program · target $300 H

$300 target

Search Psychiatry

$596 · cold demand

$596

Search Therapy

$460 · cold demand

$460

Search Dep/Anx/ADHD

$349 · cold demand

$349

PMax Local

$54

Branded

$29 · warm demand

$29

Meta Ads

N/A — Pixel not configured

N/A

Program	90d Spend	Stated CPA	Conversions	Verdict
Search · Depression / Anxiety / ADHD	$48,662 H	$349 / form-fill H	139.5 / 90d	Cold demand · highest spend
Search · Therapy Services	$31,710 H	$460 / form-fill H	69 / 90d	Cold demand · expensive
Search · Psychiatry Services	$29,820 H	$596 / form-fill H	50 / 90d	Cold demand · most expensive
PMax · Local	$8,891 H	$54 / form-fill H	165.25 / 90d	Cheap stated CPA — patient quality unverified
Branded	$5,749 H	$29 / form-fill H	197.19 / 90d	Warm-demand harvest · cheapest
Meta Ads	$2,958 H	N/A — Pixel not firing patient event	0 captured / 90d	Broken signal
Organic / SEO (5-yr incumbent)	$0 direct (agency retainer) L	N/A · GSC sync pending	~0 organic patients in 5 years H	Untracked · weak baseline
PCP Referral	$0 direct	N/A · informal	2 named (Bridgeport, Embark)	Latent · 0 formal program
Patient Referral	$0 direct	N/A · no flow	5K active panel · 0 formal flow	Latent · highest-intent

⚠

Read the table by demand stage, not stated CPA alone. Branded ($29) is warm-demand harvest; PMax ($54) leans on retargeting + local intent; Search ($349–$596) is doing net-new demand-gen Branded/PMax can't replace without funnel starvation. Reallocation calls require the patient-conversion signal to flow first.

⊕ Derived Metric — True Cost Per Treated Patient (Google Ads · blended)

Stated CPA ($201 blended) is what Google Ads measures. True cost-per-treated-patient is the business unit — and on cold-acquisition Search programs ($349–$596 stated) the derived patient CPA lands well past $1,000.

Google Spend (90d)

$124,832 H

Feb 10 → May 10, 2026

Form-fills × Funnel

621 × ~32% L

50% verify × 80% show × 80% retain

Blended Cost / Treated Patient

~$628 L

vs. $10,500 LTV

Anchored: $124,832 spend · 620.94 stated conversions — direct from Google Ads. Working assumption: 50% verification × 80% show × 80% retention — kickoff + industry-typical, none validated against EHR. Sensitivity: at 40%/70%/70%, blended true CPA ≈ $957. At 60%/85%/85%, ≈ $405. Program-level patient CPA: Branded ~$91 · PMax ~$169 · Search Dep/Anx/ADHD ~$1,090 · Search Therapy ~$1,438 · Search Psychiatry ~$1,865. Resolution: stitch EHR patient-creation events as offline conversions → 30-day cohort → upgrades L → M → H. Search-program patient CPAs likely exceed sustainable LTV ratios on cold demand.

Stated CPA · Form-fill (Google) H

Search Psychiatry

$596

Search Therapy

$460

Search Dep/Anx/ADHD

$349

PMax Local

$54

Branded

$29

Cost / Treated Patient (derived) L

Search Psychiatry

~$1,865 derived

~$1,865

Search Therapy

~$1,438 derived

~$1,438

Search Dep/Anx/ADHD

~$1,090 derived

~$1,090

PMax Local

~$169 derived

~$169

Branded

~$91 derived

~$91

⚠

Why these two charts disagree by ~3×: apply 50% verification × 80% show × 80% retention and every program's true patient CPA roughly triples. Cold-acquisition Search lands $1,000–$1,900 / patient — defensible only if those leads convert at higher LTV than Branded/PMax (a pattern the BR can't yet measure). Do not shift Search dollars to PMax based on stated CPA — form-fill quality almost certainly differs.

⊕ 13-Month Primary KPI Timeline — Google Ads Spend + Stated CPA / mo

The shape over time tells the real story. Stated CPA climbed from $96 (Sep '25) to $204 (Apr '26) — a 2.1× degradation in 7 months. May 2026 partial-month is at $297 stated CPA — the trajectory is accelerating, not flattening.

$96

$132

$107

$122

$83

$150

$141

$210

$174

$195

$200

$204

$297*

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

May 26

Anchored: stated CPA per month from Google Ads via the analytics layer — green dots = healthy ($83–$132), amber = elevated ($141+). May 2026 (*) is partial through May 10. The takeaway: Sep '25 at $83 was a leading indicator of regime change — every month since has been $141 or higher. Hypotheses to test once attribution flows: (a) competitive bidding pressure in OR/WA telehealth psychiatry; (b) keyword quality degradation post Oct '25 admin reset; (c) audience saturation. Each has a different fix.

Creative & Messaging Patterns — What's Winning vs. What's Running

⊕ Category Messaging Patterns vs. Current Creative

Telehealth psychiatry is a regulatory + trust category. Category-winning brands lead with W2 + in-state + insurance framing, founder/clinician credibility, and longitudinal patient testimonials. MindRx has all three structural advantages — and uses none of them in current creative.

↑ What's Winning in the Category

Hook

"Your provider, on payroll, on Zoom" · founder-direct credibility · payer panel named upfront · DEA NPRM context as trust signal

Format

Provider intro videos · longitudinal patient testimonials (multi-year continuity) · explainer shorts on insurance + telehealth + controlled substances

Source

First-party patient stories · clinician voice · in-state / specialty depth · regulatory framework named

Authority

Specific provider count, years in practice, payer network · W2 vs 1099 distinction · what the practice won't prescribe

⚠ What's Running Today

Hook

Generic mental-health benefits messaging — no founder voice, no W2 framing, no payer transparency

Format

Stale "Morgan" testimonials still in market (provider not on current roster) · no longitudinal patient story · 0 founder/clinician video · no DEA / W2 explainer

Source

Agency-produced stock-style creative. Anthony's voice — the moat — is absent. 200+ Healthgrades reviews exist but aren't surfaced as creative.

Authority

Generic offer-driven · no W2 distinction · no DEA NPRM context · Winter Hawks community partnership invisible on owned media

The category-winning pattern is credibility, not promotion. MindRx's W2 model + in-state-only specialty + insurance-billed commercial-only positioning is exactly what the post-Done-Global-conviction telehealth psychiatry category rewards — but it isn't appearing in the creative library. The 5-year stock of Healthgrades patient continuity stories ("she really takes the time," "responds in less than 24 hours") is the most defensible asset in the segment, given FTC enforcement on hype-prone 1099 chains.

Active Google SEARCH campaigns H

90d · 93% of Google budget

Active Meta campaigns H

live

Pixel not firing patient event

Healthgrades reviews H

200+

flagship listing · longitudinal

Surfaced as creative H

testimonials not used in market

W2 / DEA mentions in creative L

moat not in market

Creative Distribution — What's Working / Broken / Missing

↑ Working

Google Ads SEARCH at $246 stated CPA — within target band H. The SEARCH program has run 5 years and likely encodes refined keyword discipline. Stated CPA is real; patient CPA pending IntakeQ.

⚠ Broken

Meta Pixel patient-form-fill event not configured H — $1K/mo of structurally invisible spend. Stale "Morgan" testimonials still in market (provider not on current roster). Days 1-14 fix.

+ Missing

Founder/clinician voice, longitudinal patient testimonials surfaced from 200+ Healthgrades reviews, W2 + DEA NPRM framework messaging, Winter Hawks community partnership. Every structural moat is undeployed.

⊕ Healthcare Trust Pillars — What Patients Actually Respond To

Telehealth psychiatry isn't won on performance-marketing mechanics. It's won on six trust signals — and MindRx has the structural advantage to lead the category on five of them, but is currently surfacing none.

⊕ Empathy

"You'll be heard, not processed."

Healthgrades verbatim already exists ("she really takes the time"). Not surfaced as creative.

⊕ Accessibility

"Six payers. Days, not months."

Payer panel + speed-to-first appointment are structural strengths. Not on landing pages or in ad copy.

⊕ Provider Credibility

"PMHNP-BC, W2-employed, salaried — not paid per script."

The post-Done-Global category-defining message. Currently absent from all creative.

⊕ Convenience

"Zoom from your living room. Insurance handled."

100% telehealth + insurance-billed. In market — but generic, not differentiated.

⊕ Outcomes

"Continuity matters. Your provider, not a queue."

5K active panel · multi-year retention is the signal. No outcome stories in creative.

⊕ Stigma Reduction

"Psychiatric care is medical care."

Educational positioning compounds AEO + organic + paid quality score. Greenfield.

Section 3 · Category Dynamics

How telehealth psychiatry actually behaves

Seasonality, sub-segment growth, structural shifts, demand triggers. The category is undergoing a regulatory + competitive reshuffling — and MindRx sits on the favored side of every shift.

⊕ Seasonality — Annual Demand Index

Telehealth psychiatry follows a Q1 reset peak + Q4 holiday spike pattern: insurance deductible resets in January, anxiety/depression surges in November-December, summer dip on vacations and lower urgency.

11%

10%

11%

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Pattern logic: Q1 = insurance deductible resets + new-year resolutions; Q4 = anxiety/depression peak + use-it-or-lose-it deductible utilization. Summer is the dip (vacations, lower urgency). Implication: Q1 + Q4 are the prime acquisition windows — paid intensity should ramp ahead of each. L — pattern is industry-typical for behavioral health, not measured against MindRx's own 12-month traffic curve. Resolution path: backfill Google Ads + GA4 history once GSC connects.

⊕ Faster-Growth Sub-Segment

Telehealth Psychiatry · W2 + Insurance-Billed

~12-15% YoY L · industry analyst estimates · accelerated by 1099-chain implosion

PMHNP-led specialty practice is the fastest-growing healthcare workforce category per BLS projections. MindRx's W2 + in-state + insurance-billed model maps directly to where post-Done-Global-conviction patient demand is migrating.

⊕ Steady-Growth Sub-Segment

Behavioral Health · Telehealth Total

~8-10% YoY L · public-market category data (LifeStance FY25)

Driven by post-pandemic telehealth permanence + Medicare flexibility extensions through Dec 31 2026. LifeStance hit profitability inflection in FY25 ($1.42B revenue · 8,040 clinicians · $146M operating cash flow) — validates OR/WA TAM and signals M&A capacity in the regional market.

⊕ Shift 1

DEA Special Registration NPRM (Jan 17, 2025)

Federal Register proposes permanent telehealth controlled-substance prescribing framework that structurally rewards W2 + in-state + insurance-billed practices H. MindRx is on the favored side. The temporary flexibility extension runs through Dec 31 2026; the permanent rule shape is a tailwind for compliance-disciplined operators.

⊕ Shift 2

1099 telehealth chain implosion

Done Global founder convicted Nov 18 2025 — first federal prosecution of a telehealth co for illegal drug distribution H. Cerebral $3.6M DOJ settlement (Nov 2024) + $7M FTC settlement (Apr 2024). Each federal action against 1099 chains is a structural validator of MindRx's W2 model.

⊕ Shift 3

Mental-health CPC inflation + AI-search disruption

+42% YoY mental-health CPC inflation (LocaliQ 2025) H. -58% to -61% organic CTR on AI-Overview queries (Seer Sep 2025) H. Paid Google is structurally less efficient every quarter; AEO is the defensive play. MindRx has 0 organic patients in 5 years — greenfield.

⊕ Symptom-Based Search Intent — Where Patients Start

Telehealth psychiatry is a search-intent category. Patients don't search "psychiatrist near me" — they search their symptom + a treatment frame. Indexed search-volume by query class shows where the demand actually lives.

ADHD treatment online"adhd online treatment", "online adhd diagnosis", "adhd telehealth"

Very High

Online psychiatrist · medication management"online psychiatrist", "online medication management", "online psychiatric care"

Very High

Anxiety treatment online"online anxiety treatment", "telehealth anxiety", "online anxiety medication"

High

Depression treatment online"online depression treatment", "online depression medication"

High

Insurance + telehealth psychiatry"online psychiatrist that takes insurance", "psychiatrist that accepts {payer}"

High

Controlled substances · telehealth"can online psychiatrists prescribe", "telehealth adderall", "DEA telehealth"

Medium

W2 vs 1099 · marketplace concerns"is cerebral safe", "online psychiatrist not a mill", "best telehealth psychiatry"

Medium

Relative search demand L — directional from category-typical patterns, not validated against MindRx's GSC (sync pending). Every band above is a content surface. The high-volume symptom queries are where AI answer engines (Perplexity, ChatGPT, Google AI Overviews) generate parent-style summaries today — and where MindRx has zero citations. This is the structural lane the category is moving into and where the moat compounds.

⊕ Annual Demand-Trigger Timeline (DTC patient lens)

Q1 (Jan–Mar)

Insurance Reset Peak

Deductibles reset · new coverage activates · resolution-driven search peaks. Acquisition window 1 — paid intensity should ramp Dec 15.

Apr–Jun

Mid-Cycle Steady

Plateau period. Lead volume softens 15-20% relative to Q1. Best window for verification-stage SLA + landing-page testing.

Jul–Aug

Summer Dip

Vacations + lower urgency · paid efficiency lowest. Lowest acquisition window. AEO content production window.

Sep–Oct

Fall Ramp

Back-to-school anxiety + structured re-engagement · provider scheduling tightens. Acquisition window 2 — Q4 prep.

Nov–Dec

Holiday Spike + Deductible Utilization

Seasonal anxiety/depression surge + use-it-or-lose-it deductible spend. Acquisition window 3 — paid pre-plans through Q1.

Section 4 · Core Problems

5 problems, sorted by impact severity

Each problem is a Cause → Impact statement, anchored in primary data where possible. Severity badges: red = critical, amber = high, sky = medium.

Problem 1 · Critical

Patient-conversion signal isn't piped to ad platforms

⚠ CRITICAL

Google Ads optimizes against form-fill conversion events at $201 blended stated CPA H; Meta has $2,958 90d spend with 0 captured conversions (Pixel patient-form-fill event not configured) H; EHR patient-creation events not syncing back to either platform via offline conversion upload H.

Cause

No tag manager / GA4 conversion-event configuration; no offline-conversion upload pipeline from EHR; Meta Pixel never configured for the patient-form-fill event; legal review of EHR data-sharing agreement still in flight.

Impact

~$42K/mo of paid budget allocates against form-fill quality, not patient quality. Branded $29 / PMax $54 / Search $349–$596 stated CPAs almost certainly reflect demand-stage mix, not pure efficiency — reallocation calls without patient-quality signal have wide downside variance.

Problem 2 · Critical

Stated CPA has degraded 2.1× over 7 months — trajectory accelerating

⚠ CRITICAL

Monthly blended stated CPA: $96 (Sep '25) → $150 (Oct) → $210 (Dec) → $204 (Apr '26) → $297 partial-May H. The cold-acquisition Search programs are absorbing the degradation; PMax ($54) and Branded ($29) are pulling the blended down but cannot replace the demand-gen the Search programs are doing.

Cause

Working hypotheses (not findings): (a) competitive bidding pressure in OR/WA telehealth psychiatry; (b) keyword quality degradation post-Oct 2025 admin reset; (c) audience saturation in the existing keyword set. Each has a different fix — and the diagnostic requires the patient-conversion signal to differentiate.

Impact

At current trajectory, blended stated CPA hits $300+ inside 2 quarters. The verification fix recovers ~$245K/mo gross uplift M at constant spend — but only if it lands before paid efficiency collapses further.

Problem 3 · High

80/20 bimodal review distribution from Oct 2025 admin reset

HIGH

Healthgrades 5★ continuity cluster ("she really takes the time," "responds in less than 24 hours") co-exists with 1★ keyword cluster ("$480 cancellation fee," "predatory," "punishment is one sided") H. Bimodal pattern post October 2025 admin team transition.

Cause

Billing/admin operational friction during Oct 2025 admin transition. Mary Kay's billing-team rebuild + Advanced MD platform migration in flight (operations track, not MH-1 scope).

Impact

1★ cluster suppresses organic discovery + creates Google Quality Score headwind on paid CPC. Review-velocity playbook is gated on the operational fix landing — until then, prompting reviews amplifies the bimodal pattern.

Problem 4 · High

Zero AEO + zero formal referral = no compounding moat

HIGH

5 years of SEO with the incumbent agency produced ~0 organic patients H. AEO term unfamiliar to incumbent (Anthony noted at kickoff). PCP relationships informal (2 named: Bridgeport Family Medicine, Embark). 5,000 active patients with 0 formal referral flow.

Cause

SEO scope at incumbent agency was top-of-funnel content without commercial-intent targeting. PCP referral relationships managed personally by clinicians, not as a systematic acquisition channel. Patient referral flow never built.

Impact

With +42% YoY mental-health CPC inflation, the absence of compounding channels means CAC trajectory is structurally rising every quarter. Each quarter without AEO + referral compounding raises blended patient CPA.

Problem 5 · Medium

Provider hiring bottlenecked at 36-40 needed for 300-patient target

MEDIUM

13 active providers (3 onboarding, 1 interviewing) H. Capacity ceiling ~3,575 visits/mo at full utilization. 300/mo intake at 30-mo lifetime = 9,900 visits/mo = ~36-40 providers required.

Cause

120-day credentialing application + 4-month wait at slow payers (Moda). Cary at kickoff: "Interviewing isn't our strong suit." Recruiting capability is itself a deferred lever.

Impact

Even if patient acquisition lift hits 300/mo, capacity is binding well before that. Provider hiring is the deferred lever — 6-month payback, must start scoping now to align with intake-target trajectory.

Section 5 · Competitive Landscape

Where MindRx sits in the telehealth psychiatry market

Eight competitors mapped across positioning, regulatory model, and acquisition strategy. The narrative is consistent: regulatory + provider-model is the structural axis — and MindRx occupies an uncontested coordinate (W2 + in-state specialty + commercial insurance).

Positioning Map — Provider Model × Geographic Scope

X-axis: provider model (1099 marketplace ↔ W2 specialty practice). Y-axis: geographic scope (multi-state generic ↔ in-state specialty). Federal action against 1099 chains (Cerebral, Done Global) is clearing the upper-left quadrant. MindRx sits in the bottom-right — uncontested.

1099 Marketplace

W2 Specialty

Multi-State Generic

In-State Specialty

Cerebral ($3.6M DOJ)

Done Global (founder convicted)

Headway

Brightside

LifeStance

Talkiatry

Two Chairs

Mindful Therapy Group

MindRx

Strategic position: MindRx occupies the uncontested bottom-right — W2 model + in-state specialty (OR/WA only) + commercial-payer-only. The DEA NPRM tailwind structurally rewards this exact coordinate. 1099-marketplace competitors (top-left) face federal-action overhang. Multi-state W2 competitors (top-right: LifeStance $1.42B, Talkiatry $210M Series D) cannot match in-state specialty depth. The position is owned. The execution gap is geographic visibility (~0 organic patients in 5 years) + creative deployment of the moat.

Creative & Messaging Patterns

How each competitor positions and what the post-Done-Global category rewards. Client row highlighted.

Brand	Positioning	Messaging Style	Channel Strength	Where they win	Where we win
LifeStance W2 · 8K clinicians · 33 states	"Outcomes-focused practice management." Premium-clinical.	Outcome registries; clinician-led; payer-network breadth named.	Multi-state coverage + payer breadth	Geographic reach (33 states vs 2); $146M operating cash flow signals M&A capacity	In-state specialty depth; PMHNP-led model; Anthony's W2-discipline thesis
Talkiatry W2 · MD-heavy · 45 states	"Value-based behavioral health." Insurance-marketplace hybrid.	AI scribe + 60+ payers across 45 states; MD-credentialed authority.	Multi-state + payer breadth + AI ops	Series D Feb 2026 ($210M); 800+ psychiatrists	PMHNP-led specialty (BLS fastest-growing healthcare workforce); in-state continuity
Two Chairs W2 · in-home + telehealth	"In-home psychiatric care." Premium-niche.	White-glove · in-home option · therapy-led + psychiatry overlay.	Differentiated delivery (in-home)	Premium positioning · differentiated delivery	100% telehealth efficiency · OR/WA payer panel · insurance-billed only
Cerebral 1099 marketplace · multi-state	"Online mental health care, simplified." Mass marketplace.	Subscription messaging · therapist + prescriber · DTC funnel.	Paid scale + brand recognition	Brand recall + paid spend scale	$3.6M DOJ + $7M FTC settlements signal trust gap; W2 + in-state is the post-settlement category
Done Global 1099 · ADHD-focused	"Get diagnosed online." 1099 telemedicine.	Conversion-funnel-led · controlled substance access prominent.	Paid social · DTC funnel	—	Founder convicted Nov 18 2025 — structural validator of W2 model
Brightside Subscription telehealth	"Mental health care that works." Subscription DTC.	Outcomes-led · prescriber + therapy bundles · subscription model.	Paid social + subscription brand	Subscription LTV smoothness	Insurance-billed (no surprise fees) · in-state specialty depth
Headway Insurance marketplace · therapy	"Find a therapist who takes your insurance." Marketplace.	Insurance-first · therapist-discovery framing.	Paid + SEO + insurance partnerships	SEO authority on broad insurance + therapy terms	Psychiatry medication management focus (Headway is therapy-led); W2 continuity vs marketplace churn
Mindful Therapy Group PNW regional · 1099-heavy	Local PNW behavioral health network.	Local-presence messaging · therapist-led.	Local SEO + GMB	Local Portland brand recall	PMHNP-led psychiatry vs therapist-heavy; W2 + payer-panel discipline
MindRx Group W2 · OR/WA · PMHNP-led	W2 + in-state + insurance-billed psychiatric specialty.	Anthony's voice + W2 thesis is the moat — but absent from current creative.	Google Ads SEARCH (5-yr incumbent) · Healthgrades 200+	—	DEA NPRM tailwind · post-Done-Global validator · in-state specialty + 200+ longitudinal Healthgrades

Acquisition Strategy — How Each Brand Generates Demand

Brand	Primary Lever	Content Velocity	Geographic Reach	Lifecycle Leverage	SEO / AEO Authority
LifeStance	Payer partnerships + paid	Medium	33 states	Outcome registry-driven	High (clinical content)
Talkiatry	Insurance marketplace + SEO	High (AI-assisted)	45 states	EHR-led continuity	High (insurance + telehealth)
Two Chairs	Premium brand · referral	Low	Select markets	White-glove	Medium
Cerebral	Paid social · subscription	High	Multi-state	Subscription cadence	Medium (brand)
Brightside	Paid social · DTC funnel	High	Multi-state	Subscription	Medium
Headway	SEO + insurance partnerships	High	Multi-state	Marketplace	Very High (insurance+therapy)
Mindful Therapy Group	Local SEO + GMB	Medium	PNW regional	Limited	Medium-Low
MindRx Group	Google Ads SEARCH (5-yr incumbent)	Low	OR/WA only (uniquely defensible)	None active · 5K-patient panel idle	~0 (greenfield AEO)

Where MindRx Sits Today

⊕ Strategic Position

Structural advantage on regulatory model + provider model + payer panel + longitudinal patient evidence. Execution gap on creative deployment, AEO foundation, lifecycle/referral compounding, and per-channel patient measurement.

The combined moat — Anthony's W2 + in-state + insurance-billed thesis · 13 PMHNP-BC providers running near-capacity · 5,000-patient active panel · 200+ Healthgrades longitudinal reviews · DEA NPRM regulatory tailwind · post-Done-Global category validator — is genuinely defensible. It is also genuinely absent from the current creative library and undeployed across compounding channels. Multi-state W2 competitors (LifeStance, Talkiatry) out-cover on geography; 1099 marketplaces (Cerebral, Brightside) out-spend on paid; Headway out-publishes on SEO. MindRx's job over 90 days is not to replicate any of those — it's to put the actual moat into market and stitch the conversion-signal layer that lets every channel decision become defensible.

The execution gap is closeable in 90 days. Patient-conversion signal layer + verification stage fix + AEO greenfield + PCP referral + longitudinal patient testimonials are 30–60 day plays. Provider headcount expansion is the 6-month deferred lever — must start scoping now.

White Space Opportunities — Uncontested Lanes

Six lanes where no telehealth psychiatry competitor has meaningful presence and MindRx has structural fit. Three are search-intent moats; three are positioning + relationship moats.

⊕ White Space 1 · Search-Intent Moat

Symptom-Based Educational Authority

High-volume symptom queries — "ADHD treatment online," "online anxiety medication," "online psychiatrist that takes insurance" — are educational, not transactional. The pages that rank for these long-tail queries are the pages AI answer engines cite. Headway plays at the insurance-intent layer but doesn't go deep on symptom + condition education. The symptom-education lane is open and structurally compounds.

Defensibility: Very High · compounding asset · category-typical 6–9 month authority window

⊕ White Space 2 · AI Answer Engines

AEO Citations on Compliance + Insurance Questions

"Can online psychiatrists prescribe ADHD medication," "is Cerebral safe," "psychiatrist that accepts {payer}" — these AI-Overview-style queries reward compliance-disciplined, plain-language answers from licensed practices. 1099 marketplaces can't cleanly answer them (regulatory exposure); academic sources are too dense. MindRx's W2 + in-state + DEA NPRM narrative is the structurally credible voice in this lane. Citations compound; once you're in the answer set you stay.

Defensibility: Very High · category-defining regulatory tailwind · permanent moat

⊕ White Space 3 · Provider Positioning

PMHNP-Led Specialty Practice

Talkiatry is MD-heavy. Cerebral / Done Global / Brightside are 1099 marketplaces. No competitor positions explicitly as PMHNP-BC-led specialty practice with W2 employment + in-state licensing — even as BLS projects PMHNP as the fastest-growing healthcare workforce category. The lane is structurally MindRx's by professional class alone.

Defensibility: High · workforce-projection trend · 18–36 month moat

⊕ White Space 4 · Compliance Narrative

W2 · In-State · Insurance-Billed — The Post-Done-Global Category

Federal Register Jan 17, 2025 (DEA NPRM) + Done Global founder conviction Nov 18, 2025 = regulatory reward for compliance-disciplined operators. Anthony's voice on "W2, not paid-per-script · in-state, not multi-state · insurance-billed, not subscription" is the most defensible category-level positioning available — and is currently absent from market.

Defensibility: Very High · regulatory tailwind · 12–24 month brand-effect compounding

⊕ White Space 5 · Clinician-to-Clinician

PCP Referral Network (OR/WA Specialty Density)

Two informal PCP relationships exist (Bridgeport · Embark). Multi-state W2 competitors can't easily replicate — regional density beats national reach for clinician-to-clinician referral. The PMHNP-led + W2 + insurance-billed combination is the exact specialist a PCP would refer to, not a generalist marketplace.

Defensibility: Medium-High · regional density advantage · compounding relationship network

⊕ White Space 6 · Stigma Reduction

Patient-Story Continuity Library

200+ Healthgrades reviews — multi-year continuity, response-speed language, provider-specific praise — are the highest-trust signals available in the category and are currently unused as creative. Cerebral / Brightside surface anonymized star ratings; longitudinal first-person continuity stories are unique to multi-year practices. MindRx's panel makes this lane uniquely ownable.

Defensibility: High · time-in-market is the moat · compounds with every retained patient

Section 6 · Growth Opportunities

5 strategic directions, sized against measurable lift

Each opportunity is a strategic direction, not an execution plan — the tactical sequencing belongs to the 30-60-90 plan. Each carries a numeric expected-impact range and a confidence pill on the lift estimate. Three of the five (AEO authority · trust positioning · PCP referrals) are compounding moats — they don't decay when paid CPC inflates.

Opportunity 1 · Foundation

Patient-conversion signal layer

FOUNDATION

Every channel decision today optimizes against form-fill quality, not patient quality. Closing the EHR-to-ad-platform attribution loop is the prerequisite for every downstream lever — verification fix sizing, channel reallocation, AEO-vs-paid trade-off, lifecycle ROI.

Strategic Direction

Move from stated CPA as the operating KPI to cost per treated patient by closing offline-conversion sync from the patient record back to Google Ads + Meta. The shift unlocks defensible reallocation across every other lever.

Expected Impact

~70% of KPIs upgrade L→M or M→H · channel reallocation defensible · stated CPA replaced by patient CPA in operating reviews M

Why This Is Leverage

Every other opportunity is gated on this. Without it, $42K/mo of paid budget allocates on proxy quality at rising rates.

Opportunity 2 · Mechanical Lift

Verification stage fix — 50% → 75% pass rate

MECHANICAL

The verification drop-off is the largest single sensitivity in the revenue model — a stated 50% pass rate that roughly doubles effective patient CPA on every channel. Closing it is mechanical: payer-panel transparency, qualifying questions, and a same-day verification SLA. No new spend, no new channels.

Strategic Direction

Shift verification from a back-office operational task to a conversion surface. Make payer coverage and speed-to-first-appointment visible upstream of form submit, so the qualified-patient share rises at constant top-of-funnel spend.

Expected Impact

+25 patients/mo at constant spend · +$245K/mo gross uplift if pass rate moves 50% → 75% M

Why This Is Leverage

No marginal CAC. The fix lives in operational and creative layers MindRx already controls — it doesn't require partner approvals or new vendor relationships.

Opportunity 3 · Compounding Moat (Search-Intent)

AEO authority + symptom-based search visibility

COMPOUNDING

Telehealth psychiatry is a search-intent category. The patient journey starts at the symptom query ("ADHD treatment online," "online psychiatrist that takes insurance") and increasingly resolves through AI answer engines (Perplexity, ChatGPT, Google AI Overviews). MindRx is currently invisible on both fronts — zero topical authority across 5 years of incumbent SEO, zero AEO citations on category-defining queries. This is the structural lane the category is moving into.

Strategic Direction

Build a founder-authored content authority across three layers: (a) symptom-first educational content (ADHD · anxiety · depression · medication management), (b) compliance + regulatory plain-language explainers (DEA NPRM · payer panel · W2 vs 1099) that AI engines surface as authoritative, (c) longitudinal patient-story library sourced from 200+ existing Healthgrades reviews. The authority compounds; competitors can't easily replicate it because 1099 marketplaces can't speak credibly on compliance and academic sources are too dense for AI-Overview surfacing.

Expected Impact

+15–25 patients/mo by Day 90 from organic discovery + AEO citations M · ~$0 CAC at maturity · compounds 12–24 months as paid CPC inflates +42% YoY H

Why This Is Leverage

Every quarter of paid CPC inflation makes paid acquisition less viable and organic + AEO authority more valuable. Once cited by AI answer engines, the citation persists — the moat is built once and harvested for years.

Opportunity 4 · Compounding Moat (Relationship)

PCP referral network + patient referral flow

COMPOUNDING

Two informal PCP relationships (Bridgeport · Embark) and a 5,000-patient active panel with zero formal referral flow. Multi-state W2 competitors can't replicate regional density; 1099 marketplaces don't have the credibility for clinician-to-clinician referral. Each relationship compounds.

Strategic Direction

Convert the existing patient panel and clinician network from untapped relationship capital into a structured referral channel. PMHNP-led + W2 + insurance-billed is the exact specialty profile a PCP refers to — and the patient panel's multi-year continuity is the trust signal that triggers patient-to-patient referral.

Expected Impact

+5–10 patients/mo by Day 90 · effective patient CPA $50–$100 vs $700+ on cold-acquisition Search M · compounds with every retained patient + PCP relationship

Why This Is Leverage

Highest-intent acquisition source available. Margin per patient is highest. The lane is competitively defensible because national multi-state operators can't match in-state specialty density.

Opportunity 5 · Long-term (Brand + Trust)

Trust-led positioning across all 6 healthcare pillars

BRAND COMPOUNDING

The DEA NPRM tailwind + Done Global conviction = a regulatory regime that structurally rewards W2 + in-state + insurance-billed practices. MindRx has the most defensible position in the category on five of the six healthcare trust pillars (empathy · accessibility · provider credibility · outcomes · stigma reduction) and is currently surfacing none of them. The execution gap is what's keeping the moat from showing up in market.

Strategic Direction

Reframe creative + landing pages + content around the six trust pillars patients actually respond to in telehealth psychiatry — leading with provider credibility (W2 PMHNP-BC, in-state licensure, payer panel named upfront) and stigma reduction (psychiatric care is medical care). Surface longitudinal patient continuity as the proof; let convenience be the closer, not the hook.

Expected Impact

+5–10% paid CTR · reduced ad-fatigue · brand-differentiation compounding 12–24 months · L on lift sizing, H on positioning availability

Why This Is Leverage

In a category where paid CPC is rising 2.1× per 7 months, brand-level trust signals are the only mechanism that bends the CAC curve downward instead of just slowing the climb.

Section 8 · Strategic Arc

Stabilize → Scale → Compound

Strategic sequencing — not a tactical to-do list. Stabilize before scale; scale before compound. Each phase produces the conditions the next phase needs. Execution-level detail belongs to the 30-60-90 plan.

Phase 1 · Stabilize

Make the engine measurable. Fix the verification stage.

Two structural fixes have to land before anything else scales: the patient-conversion signal layer (so every channel decision is on real patient data, not a form-fill proxy) and the verification stage (so the largest single revenue-model sensitivity stops doubling effective CPA). Nothing compounds until both are real.

Priority · Patient CPA as the operating KPI

Replace stated CPA with patient CPA as the channel-performance review unit. Pre-condition for every other lever.

Priority · Verification as a conversion surface

Shift verification from a back-office operational task to upstream-of-form trust + transparency. +25 patients/mo at constant spend.

Priority · Incumbent vendor scope clarity

Define where the 5-year Search relationship continues and where compounding-moat investment begins. Avoids dual-tracking the same dollars.

Phase 2 · Scale

Reallocate with attribution. Seat the compounding channels.

With the signal layer operating, reallocation decisions move from stated to defensible. The compounding moats — AEO authority, PCP referrals, patient referrals — begin to seat. This is where the structural advantages convert into measurable demand.

Priority · Mix on patient quality, not form-fill cost

Search vs PMax vs Branded reallocation becomes a data-grounded call once attribution is real. The expensive Search programs justify their cost — or they don't.

Priority · AEO + symptom-based authority in market

Founder-authored authority on compliance + insurance + symptom education. First AI-answer-engine citations begin to land. Compounds 12–24 months.

Priority · Relationship-based acquisition activated

PCP network expands beyond two informal relationships. Patient-referral flow converts the 5K-patient panel into a demand source.

Phase 3 · Compound

Convert structural advantage into durable moat.

The trust pillars + DEA NPRM tailwind + 5-year operational depth are the assets that don't decay when paid CPC inflates. This phase puts them in market — the moat stops being theoretical and starts being measurable.

Priority · Trust-pillar positioning in market

Provider credibility · empathy · stigma reduction · outcomes — surfaced as the primary brand voice across creative and landing pages, not buried in the "About" page.

Priority · Lifecycle as a first-class channel

Once retention cohort data flows, first-month retention becomes a managed lever. The 5K-patient panel becomes a margin engine, not just a treatment base.

Priority · Provider hiring aligned with intake trajectory

The 6-month credentialing payback means hiring discipline today is what protects throughput at 300 patients/month. The deferred capacity lever scopes here.

Metric	Healthy	Trigger	Action	Owner
Google Ads stated CPA (form-fill)	<$300	>$400	Pause bottom-quartile keywords; ship 4 new ad concepts within 72 hrs	Growth
Patient CPA (derived, post-IntakeQ)	<$700	>$900	Investigate verification rate + show rate by channel; reallocate budget	Growth
Meta CPL	<$60	>$90	Refresh creative; check Pixel firing for patient event	Growth
Form-fill events / mo (GA4)	>150	<100	Audit GA4 + tag manager + UTM hygiene	Eng
Verification pass rate	>60%	<45%	Same-day verification SLA review; payer-panel landing audit	Ops
Healthgrades 1★ trailing-90d share	<10%	>18%	Billing-team operational review; pause review-prompt cadence	Ops
AEO LLM citations on target queries	≥3	0 / month 2+	Content prioritization review; founder-voice deployment	Growth

MindRx GroupBusiness Review

Funnel Performance & The Primary Growth Constraint

Channel Mix — Imbalance & Dependency Risk

Creative & Messaging Patterns — What's Winning vs. What's Running

Positioning Map — Provider Model × Geographic Scope

Creative & Messaging Patterns

Acquisition Strategy — How Each Brand Generates Demand

Where MindRx Sits Today

White Space Opportunities — Uncontested Lanes

MindRx Group
Business Review